Spyre Therapeutics (SYRE) Jefferies London Healthcare Conference 2024 summary

Key strategic initiatives

• Announced $200 million financing to fund an ambitious global platform study starting next year, testing three monotherapies and three combinations for IBD in a single, efficient trial.

• Platform study design reduces costs by 40% and accelerates development by at least two years compared to sequential studies.

• Regulatory groundwork includes open INDs for all programs, ex-U.S. approvals, and combination toxicology studies to support global development.

• Study will enroll 500 patients globally, with ethnobridging cohorts to ensure diverse representation and facilitate future pivotal trials.

Scientific and clinical advancements

• Developed next-generation antibodies targeting Alpha-4 Beta-7, TL1A, and IL-23, with plans for both monotherapy and combination use.

• Achieved unexpectedly long half-lives for Alpha-4 Beta-7 in humans, enabling potential twice-annual dosing and significant convenience improvements.

• High-concentration subcutaneous formulations allow for 2 mL auto-injectors, supporting biannual dosing regimens.

• Advancing two TL1A antibodies in parallel to mitigate immunogenicity risks and expand into additional indications beyond IBD.

Competitive landscape and differentiation

• TL1A program designed with distinct epitopes, high potency, and extended half-lives, avoiding issues seen in competitor molecules.

• No viscosity or short half-life issues; two TL1A candidates increase probability of success in IBD and other diseases.

• Proprietary biomarker strategies developed using large IBD biobank data, aiming to identify hyper-responders and optimize patient selection.

• Combination strategy leverages genetic and preclinical evidence for synergistic efficacy, with focus on safety and avoiding black box warnings.